Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline

Ceftolozane/tazobactam

Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

The FDA has accepted with Priority Review Cubist’s New Drug Application for investigational antibiotic ceftolozane/tazobactam, for which the Company is seeking FDA approval for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections…

Dificid

News & Press

22 Aug

Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review

Cubist Pharmaceuticals, Inc. today announced that the European Medicines Agency (EMA) has accepted for review the Company’s Marketing Authorization Application (MAA) for its investigational antibiotic ceftolozane/tazobactam.

Careers at Cubist

Alice

Meet Alice

Vice President of Medical Affairs, International

Alice was hired in the fall of 2013 as Vice President of Medical Affairs, International, charged with building Cubist’s Medical…

Investor Center

Cubist Pharmaceuticals Loading…
CBST (NASDAQ)